Vistagen Therapeutics Inc (VTGN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.24-1.38%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · VTGN
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Mar 2026 | Mar 2025 | Mar 2024 | |
|---|---|---|---|---|
| Revenues | ||||
| Revenues | 2.5 | 1.3 | 0.5 | 1.1 |
| Operating Expenses & Income | ||||
| R&D Expenses | 54.2 | 55.0 | 39.4 | 20.0 |
| Operating Income | (69.7) | (72.1) | (56.0) | (33.0) |
| Earnings from Continuing Operations | ||||
| EBT, Incl. Unusual Items | (67.6) | (69.7) | (51.4) | (29.4) |
| Income Tax Expense | — | 0.0 | 0.0 | 0.0 |
| Net Income | ||||
| Net Income | (67.6) | (69.7) | (51.4) | (29.4) |
| Per Share | ||||
| Basic EPS | (1.57) | (1.83) | (1.67) | (1.52) |
| Diluted EPS | (1.57) | (1.83) | (1.67) | (1.52) |
| Revenue per Share | 0.06 | — | — | — |
| Basic Weighted Avg Shares | 43.0 | 38.1 | 30.9 | 19.4 |
| Diluted Weighted Avg Shares | 43.0 | 38.1 | 30.9 | 19.4 |
| Supplemental | ||||
| EBITDA | — | (71.9) | (55.8) | (32.9) |
| EBIT | (69.7) | (72.1) | (56.0) | (33.0) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.